Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study).
Symptom changes in multiple sclerosis following psychological interventions: a systematic review.
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data.
Bruxism and temporal bone hypermobility in patients with multiple sclerosis.
Integrated genomic and prospective clinical studies show the importance of modular pleiotropy for disease susceptibility, diagnosis and treatment.
[Intractable vomiting as first manifestation of neuromyelitis Optica.]
8th FENS Forum of Neuroscience
Amiloride: a molecular probe of sodium transport in tissues and cells.
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.
Phase 3 Study of RPC1063 in Relapsing MS
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis.
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States.
The mystery of missing heritability: Genetic interactions create phantom heritability.
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis.
Ofatumumab
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α
Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis.
A promising therapeutic approach for treatment of posterior uveitis: recombinant T cell receptor ligand protects Lewis rats from acute and recurrent experimental autoimmune uveitis.
Pharmacokinetic properties and metabolism of idebenone.
Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.

Pages